Nasdaq:PETS
PETMED EXPRESS INC
A vertically integrated veterinary platform providing medical services and consumer health products across North America.
Key Metrics
Investment Thesis
Bull Case
The company possesses a unique moat through its vertically integrated model that controls both the service delivery and product manufacturing, potentially offering higher long-term margins if profitability can be restored; Its extensive network of corporate-owned clinics provides consistent cash flow streams once operational leverage kicks in; A successful turnaround in 2025 could unlock significant value given the current depressed valuation and strong brand loyalty in the pet care sector.
Bear Case
The company is currently unprofitable with two consecutive years of net losses, raising serious doubts about the sustainability of its business model without major strategic changes; Revenue has contracted significantly in the most recent year, suggesting weakening demand or competitive pressures that management has failed to address; The substantial retained earnings deficit and high capital expenditures indicate a heavy cash burden that could lead to solvency issues if profitability does not improve rapidly.
About PETMED EXPRESS INC
PETMED EXPRESS operates as a leading provider of veterinary services and products in the United States and Canada, serving pet owners through its extensive network of corporate-owned clinics. The company generates revenue primarily from medical services such as surgery, diagnostics, and emergency care, alongside branded consumer health products like Vetri9. As a vertically integrated entity, it combines clinical operations with proprietary manufacturing to offer a comprehensive ecosystem for pet wellness.
Analysis
Management Discussion
Despite revenue growth from $256.9M in 2023 to $281.1M in 2024, the company suffered a sharp decline to $227.0M in 2025, mirroring a deterioration in profitability where net income turned negative again after a brief recovery in 2023. The cash flow from operations of $4.7M was insufficient to cover the massive working capital changes of -$24.4M and capital expenditures of $5.1M, resulting in a slight net decrease in cash reserves. This pattern highlights a struggle to convert top-line sales into sustainable earnings while managing liquidity pressures.
Industry Overview
The North American veterinary industry is transitioning from a traditional care model to a value-added wellness ecosystem, driven by increasing pet ownership rates and higher spending per animal. Companies are increasingly integrating product sales with medical services to create recurring revenue streams and deepen customer relationships. Regulatory changes and supply chain dynamics continue to influence the profitability of both clinical services and consumer health products within this sector.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $256.9M | $281.1M | $227.0M |
| Cost of Revenue | $185.8M | $202.4M | $157.8M |
| Gross Profit | $71.0M | $78.6M | $69.1M |
| Operating Expenses | $72.4M | $86.8M | $70.7M |
| Operating Income | $-1.4M | $-8.2M | $-1.5M |
| G&A | $49.5M | $55.2M | $38.6M |
| Stock-Based Comp | $6.6M | $6.9M | $-6.6M |
| D&A | — | $7.1M | $7.0M |
| Depreciation | $3.5M | $5.1M | $5.1M |
| Amortization | — | $2.0M | $2.0M |
| Other OpEx | $23.0M | $31.6M | $32.0M |
| Non-Operating Income | $3.0M | $1.9M | $943.0K |
| Interest Income | $2.1M | — | — |
| Pre-Tax Income | $1.6M | $-6.3M | $-587.0K |
| Income Tax | $1.4M | $1.2M | $5.7M |
| Continuing Ops | $233.0K | $-7.5M | $-6.3M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $233.0K | $-7.5M | $-6.3M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $233.0K | $-7.5M | $-6.3M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $131.5M | $93.6M | $78.9M |
| Cash & Equivalents | $104.1M | $55.3M | $54.7M |
| Accounts Receivable | $1.7M | $3.3M | $2.3M |
| Inventory | — | — | $16.2M |
| Prepaid Expenses | $4.7M | $6.3M | $5.3M |
| Other Current Assets | $20.9M | $28.7M | $299.0K |
| Long-Term Assets | $32.7M | $76.2M | $69.8M |
| PP&E (Net) | $26.2M | $26.7M | $28.9M |
| Intangibles | $5.9M | $11.2M | $8.0M |
| Goodwill | — | $26.7M | $26.7M |
| Operating Leases | — | $1.4M | $966.0K |
| Other LT Assets | $628.0K | $5.0M | $5.3M |
| Total Assets | $164.1M | $169.9M | $148.7M |
| Current Liabilities | $36.5M | $72.2M | $62.8M |
| Accounts Payable | $25.2M | $37.0M | $23.6M |
| Current Leases | — | $459.0K | $461.0K |
| Deferred Revenue | — | $2.6M | $2.1M |
| Taxes Payable | — | — | $80.0K |
| Other Current Liab | $10.0M | $30.6M | $36.6M |
| Long-Term Liabilities | $3.8M | $995.0K | $798.0K |
| LT Operating Leases | — | $995.0K | $535.0K |
| Other LT Liab | — | $0 | $263.0K |
| Total Liabilities | $40.3M | $73.2M | $63.6M |
| Shareholders' Equity | $123.8M | $96.7M | $85.1M |
| Paid-In Capital | $18.3M | $25.1M | $18.6M |
| Retained Earnings | $105.5M | $71.6M | $66.5M |
| Total L&E | $164.1M | $169.9M | $148.7M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $233.0K | $-7.5M | $-6.3M |
| Non-Cash Adjustments | $33.5M | $-9.0K | $35.4M |
| Working Capital Changes | $-5.9M | $11.8M | $-24.4M |
| Cash from Operations | $27.8M | $4.3M | $4.7M |
| Capital Expenditures | $5.3M | $4.5M | $5.1M |
| Cash from Investing | $-10.3M | $-40.7M | $-5.1M |
| Dividends Paid | $24.5M | $12.4M | $181.0K |
| Cash from Financing | $-24.5M | $-12.4M | $-181.0K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-7.0M | $-48.8M | $-576.0K |
| Beginning Cash | $111.1M | $104.1M | $55.3M |
| Ending Cash | $104.1M | $55.3M | $54.7M |
Frequently Asked Questions
How does PETMED EXPRESS INC make money?
Corporate-owned clinic networks delivering surgical, diagnostic, and emergency care; Proprietary over-the-counter health product lines like Vetri9 manufactured in-house; Strategic partnerships with third-party providers expanding service reach.
What are the main risks for PETS?
Significant operating losses indicating potential business model inefficiencies or high cost structures relative to pricing power; Revenue contraction in 2025 suggests vulnerability to economic downturns or loss of market share; Dependence on a single dominant product line (Vetri9) creates concentration risk; High cash burn and accumulated retained earnings deficit threaten financial stability.
What is PETS's competitive advantage?
Vertical integration allowing direct control over product margins from manufacturing to clinic sales; High barriers to entry due to the capital-intensive nature of building a nationwide network of clinics; Strong brand recognition and recurring revenue potential from branded veterinary supplements.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.